Publicaciones en las que colabora con Bonaventura Clotet Sala (12)

2023

  1. Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV

    Scientific Reports, Vol. 13, Núm. 1

2022

  1. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19

    Life science alliance, Vol. 5, Núm. 4

2016

  1. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy

    JAMA - Journal of the American Medical Association, Vol. 316, Núm. 2, pp. 171-181

2015

  1. Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study

    PLoS ONE, Vol. 10, Núm. 10

  2. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

  3. Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015)

    Enfermedades infecciosas y microbiologia clinica

  4. Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio

    HIV Medicine, Vol. 16, Núm. 6, pp. 370-374

2014

  1. Peak bone mass in young HIV-infected patients compared with healthy controls

    Journal of Acquired Immune Deficiency Syndromes, Vol. 65, Núm. 2, pp. 207-212

2013

  1. Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: The RECOMB study

    HIV Medicine, Vol. 14, Núm. 6, pp. 327-336

2009

  1. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression

    Antiviral Therapy, Vol. 14, Núm. 2, pp. 195-201

2006

  1. Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment - Experienced, HIV-infected individuals: Recent data and consensus recommendations

    HIV Clinical Trials, Vol. 7, Núm. 2, pp. 86-96

2005

  1. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: Final results of the EFADITE trial

    Antiviral Therapy, Vol. 10, Núm. 7, pp. 825-832